-
Tidsskrift For Den Norske Laegeforening... Sep 2023
Topics: Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 37668127
DOI: 10.4045/tidsskr.23.0530 -
Aktuelle Urologie Aug 2023
Topics: Male; Humans; Prostatic Neoplasms, Castration-Resistant; Prostate-Specific Antigen; Taxoids
PubMed: 37541233
DOI: 10.1055/a-2084-8214 -
MMW Fortschritte Der Medizin Aug 2023
Topics: Male; Humans; Early Detection of Cancer; Prostatic Neoplasms; Prostate-Specific Antigen
PubMed: 37537437
DOI: 10.1007/s15006-023-2842-y -
Current Opinion in Urology Jan 2020In this review, we present an update on the safety and efficacy of prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) of metastatic... (Review)
Review
PURPOSE OF REVIEW
In this review, we present an update on the safety and efficacy of prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer (mCRPC).
RECENT FINDINGS
Treatment of mCRPC with approved treatment agents leads to a survival advantage. The disease often progresses despite these treatments. PRLT with Lutetium-177 and Actinium-225 labeled with PSMA (LuPSMA and AcPSMA) have recently been shown to be effective and well tolerated for mCRPC treatment. LuPSMA is currently applied in patients who have exhausted approved treatment options or in whom these approved treatments are contraindicated. In this category of heavily pretreated patients, prostate-specific antigen (PSA) response (≥50% decline) is achieved in about 46% of patients. Side-effects are tolerable with rare reports of grade III-IV treatment-induced toxicity. AcPSMA is currently applied on a smaller scale in patients who relapsed after LuPSMA or in whom LuPSMA is contraindicated. PSA response occurs in up to 88% of patients treated with AcPSMA.
SUMMARY
PRLT with LuPSMA and AcPSMA is a well-tolerated and effective treatment modality for mCRPC. Prospective randomized control trials are necessary to facilitate its application as an approved therapy option.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome
PubMed: 31644433
DOI: 10.1097/MOU.0000000000000685 -
Journal of Pharmaceutical and... Feb 2022Almost from the time of its discovery, the prostate specific antigen (PSA) has been one of the most accurate and most extensively studied indicators of prostate cancer... (Review)
Review
Almost from the time of its discovery, the prostate specific antigen (PSA) has been one of the most accurate and most extensively studied indicators of prostate cancer (PC). Because of advancements in biosensing systems and technology, PSA analysis methods have been substantially updated and enhanced as compared to their first instances. With the development of techniques in biosensor technology, the number of PSA biosensors that can be used in the biomedical sector is increasing year by year. Many different recognition elements and transducers have been used in the development of biosensor systems that exhibit high sensitivity, selectivity, and specificity. Here in this review, we provide a current overview of the different approaches to PSA detection.
Topics: Biosensing Techniques; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 34954466
DOI: 10.1016/j.jpba.2021.114535 -
The Journal of Urology Feb 2020
Topics: Humans; Lasers, Solid-State; Male; Prostate; Prostate-Specific Antigen
PubMed: 31661373
DOI: 10.1097/01.JU.0000612532.27564.25 -
The Journal of Urology Feb 2020
Topics: Humans; Lasers, Solid-State; Male; Prostate; Prostate-Specific Antigen
PubMed: 31661376
DOI: 10.1097/01.JU.0000612536.35187.24 -
Clinica Chimica Acta; International... May 2020Prostate cancer is one of the most dangerous and deadly cancers in elderly men. Early diagnosis using prostate-specific antigen (PSA) facilitates disease detection,... (Review)
Review
Prostate cancer is one of the most dangerous and deadly cancers in elderly men. Early diagnosis using prostate-specific antigen (PSA) facilitates disease detection, management and treatment. Biosensors have recently been used as sensitive, selective, inexpensive and rapid diagnostic tools for PSA detection. In this review, a variety of PSA biosensors such as aptasensors, peptisensors and immunesensors are highlighted. These use aptamers, peptides and antibodies in the biorecognition element, respectively, and can detect PSA with very high sensitivity via electrochemical, electrochemiluminescence, fluorescence and surface-enhanced Raman spectroscopy. To improve the sensitivity of most of these PSA biosensors, different nanostructured materials have played a critical role.
Topics: Aged; Biosensing Techniques; Humans; Male; Nanostructures; Nanotechnology; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 32004532
DOI: 10.1016/j.cca.2020.01.028 -
JCO Clinical Cancer Informatics Sep 2021This study examined changes in prostate disease screening (prostatic-specific antigen [PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the...
PURPOSE
This study examined changes in prostate disease screening (prostatic-specific antigen [PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the COVID-19 pandemic through December 2020.
MATERIALS AND METHODS
This analysis included test results from men ≥ 40 years, without prior International Classification of Diseases-10 record of prostate cancer since January 2016, who received PSA or prostate biopsy testing at Quest Diagnostics during January 2018-December 2020. Monthly trends were evaluated for three periods: prepandemic (January 2018-February 2020), early-pandemic (March-May 2020), and late-pandemic (June-December 2020).
RESULTS
Meeting inclusion criteria were 16,365,833 PSA and 48,819 prostate biopsy results. The average monthly number of PSA tests declined from 465,187 prepandemic to 295,786 early-pandemic (36.4% decrease; = .01) before rebounding to 483,374 (3.9% increase; = .23) late-pandemic. The monthly average number of PSA results ≥ 50 ng/mL (23,356; 0.14% of all PSA results) dipped from 659 prepandemic to 506 early-pandemic (23.2% decrease; = .02) and rebounded to 674 late-pandemic (2.3% increase; = .65). The average monthly number of prostate biopsy results decreased from 1,453 prepandemic to 903 early-pandemic (37.9% decrease; = .01) before rebounding to 1,190 late-pandemic (18.1% decrease; = .01). The average monthly number for Gleason score ≥ 8 (6,241; 12.8% of all prostate biopsies) declined from 182 prepandemic to 130 early-pandemic (28.6% decrease; = .02) and decreased to 161 late-pandemic (11.5% decrease; = .02).
CONCLUSION
The findings suggest that a substantial number of prostate screening opportunities and cancer diagnoses have been missed. Efforts are needed to bring such patients back for screening and diagnostic testing and to restore appropriate care for non-COVID-19-related medical conditions.
Topics: Biopsy; COVID-19; Early Detection of Cancer; Humans; Male; Pandemics; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 34648367
DOI: 10.1200/CCI.21.00074 -
Andrology Jul 2021
Topics: COVID-19; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; SARS-CoV-2
PubMed: 33580913
DOI: 10.1111/andr.12987